Newbio Therapeutics, Inc.

Deqiang An

Chun Yang

Nianhe Han

Peng Fei Zhu

Di Zeng

Baoxiang Wang

Huali Li

Hang Yang

Li Jian

Hang Chen

Mingzhen Li

Chengyu Hou

Liwei Song

Disclosed herein is an anti-CD79b antibody or antigen-binding fragment thereof, a drug conjugate thereof and use thereof. The anti-CD79b antibody or antigen-binding fragment thereof herein comprises: HCDR1 comprising the amino acid sequence of SEQ ID NO: 1; HCDR2 comprising the amino acid sequence of SEQ ID NO: 2; HCDR3 comprising the amino acid sequence of SEQ ID NO: 3; LCDR1 comprising the amino acid sequence of SEQ ID NO: 4; LCDR2 comprising the amino acid sequence of SEQ ID NO: 5; and LCDR3 comprising the amino acid sequence of SEQ ID NO: 6.

Anti-CD79b antibodies, drug conjugates, and applications thereof

The present invention is directed to tetramaleimide linkers and use thereof, more specifically to the compounds represented by formula I and their use in the preparation of antibody-drug conjugates (ADCs). The ADCs obtained from the tetramaleimide linkers have high homogeneity and stability, and could be used effectively for the treatment of various diseases including tumors. The definition of the groups in formula I is the same as that in the description. 

Tetramaleimide linkers and use thereof

The present invention is directed to oxadiazole linkers and use thereof, more specifically to the compounds represented by formula I, II, and III, and their use in the preparation of antibody-drug conjugates (ADCs). The ADCs obtained from said oxadiazole linkers have high homogeneity and stability, and could be used effectively for the treatment of various diseases including tumors. The definition of the groups in formula I, II, and III is the same as that in the description. 

Oxadiazole linkers and use thereof

Disclosed are a type of tridentate linkers and use thereof. The tridentate linkers can be used to prepare an antibody drug conjugates as represented by formula I,L-(T-A-D)&#x2003;&#x2003;Iwherein, L is an antibody, antibody fragment or protein; T is a tridentate linker part; A is a cleavable linker group or a noncleavable linker part; D is a drug part; n is an integer of 0-8. The structure of the tridentate linker part is as represented by formula II, wherein, W is substituted aryl, heteroaryl, linear alkyl, cycloalkyl, heterocycloalkyl, or any combination thereof.

Tridentate connexon and use thereof

Derivatives of dolastatin 10 and uses thereof, the structures of which are shown as formula I, II, III and IV are provided. 

Derivatives of dolastatin 10 and uses thereof

A type of trimaleimide linkers and uses thereof are disclosed. The trimaleimide linkers can be applied for preparation of antibody-drug conjugate as shown by formula I: L-(T-A-D)I wherein, L is an antibody, antibody fragment or protein; T is a trimaleimide linker; A is a cleavable linker group or a noncleavable linker; D is a drug; n is an integer ranging from 1 to 8.

Growing community of inventors

Shanghai, China

Deqiang An